You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Programming Metabolically Fit TILs for Immunotherapy

    SBC: Lipo-immuno Tech, LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a vaccine to prevent Pneumocystis pneumonia

    SBC: NXT BIOLOGICS, INC.            Topic: NIAID

    Despite the fact that fungal diseases are an increasing clinical burden, particularly among immunocompromised patients, there are no anti-fungal vaccines approved for clinical use. The fungal opportunistic pathogen, Pneumocystis jirovecii is the causative agent of Pneumocystis pneumonia (PCP), which remains a serious AIDS-defining, opportunistic infection and is of increasing concern in persons re ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GlycoScientific, L.L.C.            Topic: 300

    Project Summary/Abstract The ability to accurately quantitate the glycan chains attached to glycoproteins has wide-ranging implications. Numerous studies over the past 40 years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers, and demonstrates the potential of using glycan markers in either a diagnostic or a prognostic manner. The glycosylation on recomb ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Delivery of chemically modified PNA oligomers

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Feasibility Study of HIF2A Inhibitor PT2385 to Treat Muscle Strain Injury

    SBC: HAWA Therapeutics LLC            Topic: OD

    ABSTRACT Multi-PIs: Yin, A (HAWA Therapeutics) and Yin, H (UGA) Muscle strain injury (also called pulled muscle or eccentric contraction-induced muscle injury) is a common health problem affecting everyone in daily life. A mildly strained muscle may recover completely within one to two weeks; whereas moderate-to-severe muscle strains usually result in a prolonged and incomplete recovery with persi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Multi NA-based influenza vaccines

    SBC: ADVAC LLC            Topic: NIAID

    PROJECT SUMMARY Current influenza (flu) vaccination inducing strain-specific immunity against variable hemagglutinin (HA) proteins is suboptimal for providing cross protection against antigenically-different epidemic strains and unanticipated new pandemic viruses. Development of an effective flu vaccine inducing enhanced cross protection against viruses with different HA variants is a high priorit ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Decellularized xenograft leaflet patch for pulmonary valve repair in pediatric patients

    SBC: TGen Tech, LLC            Topic: NIBIB

    Congenital heart disease affects approximately 40,000 newborns each year in the U.S. Valve repairs are needed for pulmonary valve, particularly for patients with the diagnoses of tetralogy of Fallot, tetralogy of Fallot with absent pulmonary valve, tetralogy of Fallot with AV canal, pulmonary valvar stenosis, and pulmonary valvar atresia. An additional group are patients with a prior repair of tet ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Improving data capture in clinical research using a chatbot

    SBC: Dokbot, LLC            Topic: NLM

    PROJECT SUMMARY . Collecting complete and accurate outcome data directly from research participants is becoming increasingly important. Clinical researchers needs a cost-effective approach to capture high-quality patient-reported outcomes. Typically, data captured directly from participants is through self-administered questionnaires or through a human interviewer, each with their own advantages ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Analysis of new compounds to treat familial hypercholesterolemia

    SBC: GRUTHAN BIOSCIENCE LLC            Topic: NHLBI

    PROJECT SUMMARY The long-term goal of the current proposal is to generate a new class of small molecules to treat familial hypercholesterolemia. Familial hypercholesterolemia (FH) patients suffer from excessively high levels of Low Density Lipoprotein Cholesterol (LDL-C), which if left untreated results in death from severe cardiovascular disease. FH is caused primarily by mutations in the LDL rec ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel MRI Contrast Agent for Early Detection of Alcoholic Steatohepatitis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: 999

    Abstract Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide[1-4]. Hepatic fibrosis can develop in patients with any type of chronic liver disease (CLD), including alcoholic liver disease (ALD), hepatitis C, hepatitis B, nonalcoholic fatty liver disease (NAFLD) and autoimmune hepatitis. The major clinical consequences of cirrhosis are liver failure and hepatocellular ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government